A phase II study of CCI-779 [temsirolimus] in combination with bevacizumab in stage III or IV melanoma.

Trial Profile

A phase II study of CCI-779 [temsirolimus] in combination with bevacizumab in stage III or IV melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Planned End Date changed from 1 Jun 2010 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top